Piper Jaffray Cuts Arena Pharma (ARNA) to Neutral
Tweet Send to a Friend
Get Alerts ARNA Hot Sheet
Price: $7.51 +0.13%
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade ARNA Now!
Piper Jaffray's Edward Tenthoff downgraded shares of Arena Pharma (NASDAQ: ARNA) from Overweight to Neutral Wednesday morning. The analyst maintained a $2.50 price target.
The stock is down more than 4.5 percent in pre-market action. Shares last traded at $3.11.
For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The stock is down more than 4.5 percent in pre-market action. Shares last traded at $3.11.
For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Arena Pharmaceuticals (ARNA) Weakens Mid-Day
- Goldman Sachs Downgrades Rubicon Technology (RBCN) to Sell
- Goldman Sachs Downgrades Charles River Labs (CRL) to Sell; Sees 12% Downside
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
Piper Jaffray
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
